Table 2.
Biomarkers measures compared according to the clinical conversion at follow-up.
| SAMPLE |
AD |
FTD |
DLB |
Stable |
Reverter |
Total |
P-value |
|
|---|---|---|---|---|---|---|---|---|
| N | 39 | 10 | 1 | 27 | 3 | 80 | – | |
| CSF Aβ42 (ng/l) | Mean | 416.4* | 750.3 | 200 | 721.7 | 578.7 | 562.7 | <0.001 |
| SD | 194.9 | 233.8 | – | 319.7 | 152.7 | 289.4 | ||
| Positive < 500 (ng/l) | N | 31* | 1 | 1 | 8 | 1 | 42 | <0.05 |
| CSF t-Tau (ng/l) | Mean | 595.7 | 479.7 | 521.0 | 367.0 | 180.0 | 488.8 | ns |
| SD | 448.9 | 351.1 | – | 209.4 | 46.2 | 375.1 | ||
| Positive > 450 (ng/l) | N | 21* | 4 | 1 | 9 | 0 | 35 | <0.05 |
| CSF p-Tau (ng/l) | Mean | 83.8* | 64.7 | 59.0 | 56.6 | 45.3 | 70.8 | 0.01 |
| SD | 34.9 | 40.8 | – | 30.1 | 5.1 | 35.7 | ||
| Positive > 61 (ng/l) | N | 29* | 5 | 0 | 11 | 0 | 45 | <0.05 |
| CSF p-Tau/Aβ42 ratio | Mean | 0.2* | 0.1 | 0.3 | 0.1 | 0.08 | 0.17 | <0.01 |
| SD | 0.14 | 0.06 | – | 0.1 | 0.01 | 0.13 | ||
| CSF t-Tau/Aβ42 ratio | Mean | 1.6* | 0.7 | 2.6 | 0.7 | 0.3 | 1.2 | <0.05 |
| SD | 1.2 | 0.5 | – | 0.63 | 0.01 | 1.1 | ||
| FDG-PET ‘AD’ pattern | N | 35* | 3 | 0 | 5 | 0 | 43 | <0.05 |
| FDG-PET ‘FTD’ pattern | N | 1 | 7* | 0 | 9* | 0 | 17 | <0.05 |
| FDG-PET “DLB” pattern | N | 0 | 0 | 1* | 0 | 0 | 1 | <0.05 |
| FDG-PET ‘negative’ pattern | N | 3 | 0 | 0 | 13* | 3* | 19 | <0.05 |
Abbreviations: CSF = cerebrospinal fluid; t-Tau = total Tau; p-Tau = phosphorylated Tau; AD = Alzheimer's disease, FTD = frontotemporal dementia, DLB = dementia with Lewy bodies. Statistical differences were assessed performing ANOVA and Chi-square analyses.
*
Significance at p < 0.05.